Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 23 | 1 | 21 | −1 |
| Shares | 7.14M | 72.8K | 7.17M | +96.6K (+1.4%) |
| Value | $21.1M | $214.8K | $20.4M | −$431.2K (−2.1%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 79,833 | $227.5K | 0.00% |
| Bryn Mawr Trust Co | 250 | $713 | 0.00% |
| Danske Bank A/S | 1 | $3 | 0.00% |
Sold out (4)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Renaissance Technologies LLC | 10,418 | $30.7K |
| The PNC Financial Services Group, Inc. | 500 | $1.48K |
| Riggs Asset Managment Co. Inc. | 50 | $148 |
| Qube Research & Technologies Ltd | 1 | $3 |
Not filed for Q3 2024 yet (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 72,827 | $214.8K |